Patent · US Active

Combined markers for metastatic cancer and uses thereof

US12174190B2 · kind B2 · utility

0Cited by
0References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 18, 2018
Grant dateDec 24, 2024
Priority date
Expiry dateDec 15, 2041

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG16H30/00
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

A combination of markers (TMEM, MenaCalc, and MenalNV) for hematogenous metastatic cancer and their use for diagnosis, prognosis and predictive performance are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.